Trius Therapeutics to Present Experimental Antibiotic Study Results at ECCMID Meeting

Trius Therapeutics to Present Experimental Antibiotic Study Results at ECCMID
Meeting

SAN DIEGO, April 23, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc.
(Nasdaq:TSRX) announced today that the results of a large, late-stage human
study, called ESTABLISH 2, and multiple other clinical studies from its
experimental antibiotic, tedizolid phosphate (TR-701), will be presented in
poster and oral presentations at the European Congress of Clinical
Microbiology and Infectious Diseases (ECCMID) meeting in Berlin from April
27-30. A total of three tedizolid-related posters and one oral presentation
have been accepted for presentation, including clinical and safety results.

The clinical abstracts examine the effect of tedizolid in patients with acute
bacterial skin and skin structureinfections (ABSSSI), as well as cardiac and
medication interaction safety trials. The abstracts include a poster
presentation from the ESTABLISH 2 trial, the second of two late-stage or Phase
3 studies needed for U.S. and E.U. regulatory filings. As in the ESTABLISH 1
study, which tested the pill form of tedizolid, the ESTABLISH 2 intravenous
(IV) to pill transition study captured the endpoints for ABSSSI established by
both the U.S. Food and Drug Administration (FDA) and the European Medicines
Agency (EMA). These presentations mark the first time ESTABLISH 2 data are
being presented at a major medical meeting. Top-line results, reported in
March 2013, showed that tedizolid achieved all primary and secondary efficacy
outcomes after a short course of therapy using one-tenth the amount of total
drug versus the comparator linezolid (Zyvox^®). Patients receiving tedizolid
also showed numerical improvements in key safety and tolerability measurements
in the complete study population.

"The results of ESTABLISH 2 combined with those from ESTABLISH 1 and
additional clinical studies support the differentiated profile of tedizolid as
a potential new treatment option for patients with severe skin infections,"
said Dr. Philippe Prokocimer, Chief Medical Officer of Trius.

Tedizolid is the company's lead product candidate. It is a once daily, IV and
orally administered oxazolidinone being developed for the treatment of serious
gram-positive infections, including those caused by methicillin-resistant
Staphylococcus aureus (MRSA).

The presentations are as follows:

Saturday, April 27th

  Poster Session – PK/PD: New Drugs, the Critically and Resistant Bugs (3:30
  p.m. – 4:30 p.m.)

    *P 921: Lack of pharmacokinetic drug interaction of tedizolid phosphate
      with pseudoephedrine in healthy subjects; S. Flanagan, S. Minassian,
      K.A. Munoz, H. Dreskin, E. Fang, P. Prokocimer

Sunday, April 28th

  Poster Session – Late Breaking News (1:30 p.m. – 2:30 p.m.)

    *LB 2964: Efficacy and safety results from the ESTABLISH 2 ABSSSI study
      comparing  IV and oral tedizolid phosphate and linezolid; E. Fang, C. De
      Anda, A. Das, P. Prokocimer

  Poster Session – New Antibacterial Agents Other than Beta-lactams (1:30 p.m.
  – 2:30 p.m.)

    *P 1648: Effects of oral tedizolid phosphate on QTcF and other
      electrocardiogram (ECG) parameters; E. Fang, J. Litwin, W. Lewis, C.
      Casseday, S.L. Minassian, S. Flanagan, P. Prokocimer

Monday, April 29th

  Oral Presentation – Emerging Resistance in Gram-Positive Bacteria (11:30
  a.m. – 12:30 p.m.)

    *O 449: Identification and characterization of linezolid-resistant
      Staphylococcus aureus 3133832, the first known clinical isolate
      possessing the cfr multidrug-resistance gene; K. Shaw, J. Locke, D.
      Zuill, D. Sahm, J. Deane, G. A. Denys

Copies of these posters will be available on the Trius website following the
ECCMID meeting:
http://www.triusrx.com/trius-therapeutics-news-posters-publications-year.php.

About Trius Therapeutics

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of innovative antibiotics for
serious infections. The Company's lead investigational drug, tedizolid
phosphate, is a novel antibiotic in Phase 3 clinical development for the
treatment of serious gram-positive infections, including those caused by
methicillin-resistant Staphylococcus aureus (MRSA). Trius has partnered with
Bayer HealthCare for the development and commercialization of tedizolid
phosphate outside of the U.S., Canada and the European Union. In addition to
the Company's tedizolid phosphate clinical program, Trius has initiated
Investigational New Drug (IND) enabling studies for its Gyrase-B development
candidate with potent activity against Gram-negative bacterial pathogens
including multi-drug resistant strains of E. coli, Klebsiella, Acinetobacter
and Pseudomonas.For more information, visit www.triusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such statements are
subject to risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such statements
include, but are not limited to, statements regarding the anticipated effects
of the addition of Mr. Fischer to the Company's Board of Directors and the
Company's commercialization efforts. Risks that contribute to the uncertain
nature of the forward-looking statements include: the accuracy of Trius'
estimates regarding expenses, future revenues and capital requirements; the
success and timing of Trius' preclinical studies and clinical trials;
regulatory developments in the United States and foreign countries; changes in
Trius' plans to develop and commercialize its product candidates; additional
ongoing or planned clinical trials of tedizolid phosphate may produce negative
or inconclusive results; Trius may decide, or the FDA may require Trius, to
conduct additional clinical trials or to modify Trius' ongoing clinical
trials; Trius may experience delays in the commencement, enrollment,
completion or analysis of clinical testing for its product candidates, or
significant issues regarding the adequacy of its clinical trial designs or the
execution of its clinical trials, which could result in increased costs and
delays, or limit Trius' ability to obtain regulatory approval; the third
parties with whom Trius has partnered with for the development of tedizolid
phosphate and upon whom Trius relies to conduct its clinical trials and
manufacture its product candidates may not perform as expected; tedizolid
phosphate may not receive regulatory approval or be successfully
commercialized; unexpected adverse side effects or inadequate therapeutic
efficacy of tedizolid phosphate could delay or prevent regulatory approval or
commercialization; Trius' ability to obtain and maintain intellectual property
protection for its product candidates; and the loss of key scientific or
management personnel. These and other risks and uncertainties are described
more fully in Trius' most recent Form 10-K, Forms 10-Q and other documents
filed with the United States Securities and Exchange Commission, including
those factors discussed under the caption "Risk Factors" in such filings. All
forward-looking statements contained in this press release speak only as of
the date on which they were made. Trius undertakes no obligation to update
such statements to reflect events that occur or circumstances that exist after
the date on which they were made.

CONTACT: Public Relations Contact:
         Laura Kempke/Andrew Law at MSLGROUP
         trius@mslgroup.com
         781-684-0770
        
         Investor Relations Contact:
         Stefan Loren at Westwicke Partners, LLC
         sloren@westwicke.com
         443-213-0507